US FDA Accepts Sun Pharma’s NDA for Dry Eye Candidate

December 29, 2017: By Jon Swedien

The US FDA has accepted Sun Pharmaceutical Industries’ new drug application (NDA) for OTX-101 for dry eye disease, the company announced Dec. 27.

OTX-101 (cyclosporine A, ophthalmic solution) 0.09% is a novel nanomicellar formulation in a clear, preservative-free aqueous solution. The NDA was filed by Sun Pharma’s wholly owned subsidiary, Sun Ophthalmics.

If approved, OTX-101 would be the third pharmaceutical drug for dry eye disease approved in the US market.

In a 12-week, multicenter, randomized, double-masked Phase III confirmatory study, 744 dry eye patients were treated either with OTX-101 or its vehicle. After the 12 weeks of treatment, OTX-101 showed statistically significant improvement in the primary endpoint, Schirmer’s score (p<0.0001), compared with vehicle, Sun Pharma said.

The study demonstrated the potential of OTX-101 to offer patients improved tear production with faster onset of action, Sun Pharma said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023